PHRX — Pharmadrug Cashflow Statement
0.000.00%
Last trade - 00:00- CA$1.08m
- CA$2.69m
Annual cashflow statement for Pharmadrug, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
C2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -4.28 | -3.06 | -13.3 | -0.873 | -0.433 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.272 | 0.889 | 13.3 | 0.369 | 0.193 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.133 | 0.087 | 0.294 | -0.303 | 0.101 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -4.13 | -2.26 | -0.672 | -0.757 | -0.088 |
| Capital Expenditures | -0.043 | — | — | -0.012 | 0 |
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 1.52 | 0.078 | 0.995 | 0 | — |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 1.48 | 0.078 | 0.995 | -0.012 | 0 |
| Financing Cash Flow Items | -0.177 | -0.145 | 0.222 | -0.004 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.777 | 0.843 | 0.226 | 0.322 | 0 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1.18 | -0.949 | 0.552 | -0.449 | -0.088 |